Letrozole Crescent Pharma

Letrozole, the active ingredient in Letrozole Crescent Pharma, is an aromatase inhibitor presented as a tablet for oral use. It works by selectively inhibiting the aromatase enzyme, thereby reducing peripheral conversion of androgens to estrogens. It lowers estrogen production and is used to treat hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company provides bulk and packaged quantities to hospitals, pharmacies and procurement teams under strict quality standards.

Letrozole is indicated for hormone‑driven breast cancer pathways, primarily in postmenopausal patients.

Hormone receptor‑positive breast cancer (postmenopausal): reduces risk of disease recurrence and progression. Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer (postmenopausal): improves disease‑free survival. Metastatic hormone receptor‑positive breast cancer (postmenopausal): delays tumor growth.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature. - Joint and muscle pain: arthralgia or myalgia often reported. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate gastrointestinal upset. - Increased cholesterol: elevation of serum lipid levels. - Bone density loss: reduced bone mineral density over time.

Serious or Rare Side Effects: - Severe liver injury: jaundice or hepatitis requiring monitoring. - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Osteoporotic fractures: increased risk of hip or vertebral fractures. - Cardiovascular events: myocardial infarction or stroke. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating letrozole therapy, clinicians should evaluate several safety considerations.

Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. Assess cardiovascular risk: watch for hypertension or thromboembolic events. Check liver function: adjust use if hepatic impairment is present. Avoid use in pregnancy: teratogenic risk; contraindicated in pregnant or nursing women. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent estrogen‑containing hormone therapy: negates therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Tamoxifen: potential antagonistic effect on estrogen pathways. - Warfarin: possible alteration of anticoagulant effect. - Antidepressants metabolized by CYP2A6: monitor for altered levels.